0
Your cart

Your cart is empty

Books > Medicine > Clinical & internal medicine > Diseases & disorders > Immunology

Buy Now

Resistance to Targeted Therapies in Multiple Myeloma (Hardcover, 1st ed. 2021) Loot Price: R4,225
Discovery Miles 42 250
Resistance to Targeted Therapies in Multiple Myeloma (Hardcover, 1st ed. 2021): Silvia CW Ling, Steven Trieu

Resistance to Targeted Therapies in Multiple Myeloma (Hardcover, 1st ed. 2021)

Silvia CW Ling, Steven Trieu

Series: Resistance to Targeted Anti-Cancer Therapeutics, 22

 (sign in to rate)
Loot Price R4,225 Discovery Miles 42 250 | Repayment Terms: R396 pm x 12*

Bookmark and Share

Expected to ship within 10 - 15 working days

Multiple Myeloma remains an incurable malignancy. As the disease progresses, it invariably becomes resistant to treatment and almost all patients develop refractory disease. There are multiple different types of targeted therapies and many of them are used in combination at different stages of disease. Targeted therapies that are approved to be used include Proteasome Inhibitors, Immunomodulatory Drugs and Monoclonal Antibodies. Second and third generations of these drugs are developed to overcome resistance and they have unique mechanism of actions. Targeted therapies that are undergoing clinical trials include CAR-T cells, bi-specific antibodies, vaccines, ubiquitin ligase inhibitors and BCL-2 inhibitors. This book will help to develop an understanding of targeted therapies in Multiple Myeloma. Its goal is to provide a unique review of the mechanism of action and resistance of the many targeted therapies in Multiple Myeloma by leaders of the field. The book will be useful for students in medical science, clinicians, health professionals, scientists, pharmaceutical professionals, drug developers, and policy makers. This book will provide an insightful knowledge of the biology of Multiple Myeloma, the mechanism of action and resistance of targeted therapies, application of biomarkers and genomics and possible strategies in overcoming resistance and future development.

General

Imprint: Springer Nature Switzerland AG
Country of origin: Switzerland
Series: Resistance to Targeted Anti-Cancer Therapeutics, 22
Release date: July 2021
First published: 2021
Editors: Silvia CW Ling • Steven Trieu
Dimensions: 235 x 155mm (L x W)
Format: Hardcover
Pages: 154
Edition: 1st ed. 2021
ISBN-13: 978-3-03-073439-8
Categories: Books > Medicine > Clinical & internal medicine > Diseases & disorders > Oncology > General
Books > Medicine > Clinical & internal medicine > Diseases & disorders > Immunology > General
LSN: 3-03-073439-0
Barcode: 9783030734398

Is the information for this product incomplete, wrong or inappropriate? Let us know about it.

Does this product have an incorrect or missing image? Send us a new image.

Is this product missing categories? Add more categories.

Review This Product

No reviews yet - be the first to create one!

Partners